193 related articles for article (PubMed ID: 31673107)
1. Structure Based Multitargeted Molecular Docking Analysis of Selected Furanocoumarins against Breast Cancer.
Acharya R; Chacko S; Bose P; Lapenna A; Pattanayak SP
Sci Rep; 2019 Oct; 9(1):15743. PubMed ID: 31673107
[TBL] [Abstract][Full Text] [Related]
2. In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
J Mol Model; 2021 Dec; 28(1):17. PubMed ID: 34962586
[TBL] [Abstract][Full Text] [Related]
3. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
4. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
5. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
[TBL] [Abstract][Full Text] [Related]
6. DESIGN, SYNTHESIS, MOLECULAR DOCKING AND ANTI-BREAST CANCER ACTIVITY OF NOVEL QUINAZOLINONES TARGETING ESTROGEN RECEPTOR α.
Ahmed MF; Youns M; Belal A
Acta Pol Pharm; 2016; 73(1):115-27. PubMed ID: 27008806
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
8.
Maruthanila VL; Elancheran R; Mirunalini S
Curr Comput Aided Drug Des; 2022; 18(3):196-212. PubMed ID: 35598239
[TBL] [Abstract][Full Text] [Related]
9. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
Mol Divers; 2023 Jun; 27(3):1141-1162. PubMed ID: 35737256
[TBL] [Abstract][Full Text] [Related]
12. Structure Based docking studies towards exploring potential anti-androgen activity of selected phytochemicals against Prostate Cancer.
Singh AN; Baruah MM; Sharma N
Sci Rep; 2017 May; 7(1):1955. PubMed ID: 28512306
[TBL] [Abstract][Full Text] [Related]
13. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the Anti-Cancer Potential of Onoceranoid Triterpenes from
Hardianto A; Mardetia SS; Destiarani W; Budiman YP; Kurnia D; Mayanti T
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834479
[TBL] [Abstract][Full Text] [Related]
15. Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF-7/SC Breast Cancer Cells.
To NB; Truong VN; Ediriweera MK; Cho SK
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232636
[TBL] [Abstract][Full Text] [Related]
16. In Silico docking studies of selected flavonoids--natural healing agents against breast cancer.
Suganya J; Radha M; Naorem DL; Nishandhini M
Asian Pac J Cancer Prev; 2014; 15(19):8155-9. PubMed ID: 25338999
[TBL] [Abstract][Full Text] [Related]
17.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
18. An In silico Approach to Identify High Affinity Small Molecule Targeting m-TOR Inhibitors for the Clinical Treatment of Breast Cancer.
Patidar K; Panwar U; Vuree S; Sweta J; Sandhu MK; Nayarisseri A; Singh SK
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1229-1241. PubMed ID: 31030499
[TBL] [Abstract][Full Text] [Related]
19. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
